Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine versus no anticancer treatment for pediatric AML in molecular relapse after first complete remission
NL-OMON44834Phase 2Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Dec 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of azacitidine in acute myeloid leukemia (AML) (3 arms), sponsored by Celgene Corporation. Primary endpoints: Safe and tolerable dose identification, Dose-limiting toxicities and 2 more. Started Dec 2016; status: active, not recruiting.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON44834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44834.